- Home
- TECX vs RCKT Comparison
TECX vs RCKT Comparison
Compare TECX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- RCKT
- Stock Information
- Founded
- TECX 2019
- RCKT 1999
- Country
- TECX United States
- RCKT United States
- Employees
- TECX N/A
- RCKT N/A
- Industry
- TECX
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- TECX
- RCKT Health Care
- Exchange
- TECX Nasdaq
- RCKT Nasdaq
- Market Cap
- TECX 334.4M
- RCKT 326.4M
- IPO Year
- TECX 2018
- RCKT N/A
- Fundamental
- Price
- TECX $19.81
- RCKT $2.70
- Analyst Decision
- TECX Buy
- RCKT Buy
- Analyst Count
- TECX 7
- RCKT 13
- Target Price
- TECX $78.67
- RCKT $18.50
- AVG Volume (30 Days)
- TECX 156.7K
- RCKT 8.4M
- Earning Date
- TECX 08-13-2025
- RCKT 08-04-2025
- Dividend Yield
- TECX N/A
- RCKT N/A
- EPS Growth
- TECX N/A
- RCKT N/A
- EPS
- TECX N/A
- RCKT N/A
- Revenue
- TECX N/A
- RCKT N/A
- Revenue This Year
- TECX N/A
- RCKT N/A
- Revenue Next Year
- TECX N/A
- RCKT N/A
- P/E Ratio
- TECX N/A
- RCKT N/A
- Revenue Growth
- TECX N/A
- RCKT N/A
- 52 Week Low
- TECX $13.70
- RCKT $2.19
- 52 Week High
- TECX $61.07
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- TECX 40.56
- RCKT 32.09
- Support Level
- TECX $22.13
- RCKT $2.66
- Resistance Level
- TECX $25.75
- RCKT $3.33
- Average True Range (ATR)
- TECX 1.44
- RCKT 0.28
- MACD
- TECX -0.48
- RCKT 0.09
- Stochastic Oscillator
- TECX 10.68
- RCKT 26.59
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.